Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premium Land study
jRCT2011180004Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of landiolol in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Relapse-free survival and Overall survival. Started Jan 2019; status: completed.
02
Drugs
landiolol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2011180004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011180004.